Compare HIT & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIT | NSPR |
|---|---|---|
| Founded | 1964 | 2005 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Specialty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 72.1M |
| IPO Year | N/A | 2009 |
| Metric | HIT | NSPR |
|---|---|---|
| Price | $0.99 | $0.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.25 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 274.6K | 267.5K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | $41.00 | $57.98 |
| Revenue Next Year | $69.63 | $95.41 |
| P/E Ratio | $52.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.86 |
| 52 Week High | $4.01 | $2.93 |
| Indicator | HIT | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.72 | 33.23 |
| Support Level | N/A | N/A |
| Resistance Level | $1.81 | $1.29 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 20.37 | 19.28 |
Health In Tech Inc is an AI-enabled insurance technology platform company that offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, it streamlines the underwriting, sales, and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs), and third-party administrators (TPAs). The company's platform serves as a marketplace for brokers, TPAs, MGUs and carriers with self-funded health insurance options for employers. The platform includes functions such as plan customization, stop-loss quoting, underwriting, claims administration, and reporting integration.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.